A Betamethasone-Calcipotriene Combination for Psoriasis
Taclonex ointment (Warner Chilcott/LEO Pharma), a combination of the vitamin D3 analog calcipotriene 0.005% (Dovonex) and the high-potency corticosteroid betamethasone dipropionate 0.064%, was recently approved by the FDA for treatment of psoriasis vulgaris in patients ≥ 18 years old....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: A Betamethasone-Calcipotriene Combination for Psoriasis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1238
Article Code: 1238c
Date: July 3, 2006
Volume: 48
Pages: 55-56
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1238
Article Code: 1238c
Date: July 3, 2006
Volume: 48
Pages: 55-56
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)